Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06466187 · ClinicalTrials.gov registry record · Phase 1

A Study of SGN-MesoC2 in Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
19
Enrollment target
20
Study locations

NCT06466187 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 19 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06466187, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
19 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.

Conditions Studied

Carcinoma, Non-Small Cell Lung Pancreatic Adenocarcinoma Colorectal Neoplasms Mesothelioma Ovarian Neoplasms Other Solid Tumors Endometrial

Interventions

  • DRUG PF-08052666

Study Locations (20)

Kansas

  • The University of Kansas Clinical Research Center - Fairway
  • The University of Kansas Hospital Cambridge North Tower A - Kansas City
  • The University of Kansas Hospital - Kansas City
  • The University of Kansas Medical Center Medical Office Building - Kansas City
  • The University of Kansas Cancer Center - Indian Creek Campus - Overland Park
  • The University of Kansas Cancer Center - Westwood - Westwood
  • The University of Kansas Cancer Center, Investigational Drug Services - Westwood

Alabama

  • University of Alabama at Birmingham - Birmingham
  • The University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham
  • The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham - Birmingham

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville

Utah

  • START Mountain Region, LLC - Salt Lake City
  • START Mountain Region - West Valley City

Ontario

  • University Health Network - Toronto
  • University Health Network, Princess Margaret Cancer Centre - Toronto

North Carolina

  • Atrium Health Wake Forest Baptist - Winston-Salem

Texas

  • START San Antonio, LLC - San Antonio

Quebec

  • The Research Institute of the McGill University Health Centre - Montreal

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2024-08-02
Est. Completion 2029-05-01
Phase Phase 1

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06466187

The ClinicalTrials.gov registry entry for NCT06466187 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which PF-08052666 is the first listed.

NCT06466187 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Kansas, Alabama, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06466187 about?

NCT06466187 is a clinical study titled "A Study of SGN-MesoC2 in Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...

What is the current status of trial NCT06466187?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-08-02. Estimated completion is 2029-05-01.

What conditions does trial NCT06466187 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Ovarian Neoplasms.

What interventions are being tested in trial NCT06466187?

The interventions under investigation include: PF-08052666 (DRUG).

Who is sponsoring clinical trial NCT06466187?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06466187 being conducted?

This trial has 20 study locations across Alabama, Kansas, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Pancreatic Adenocarcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.